- Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
- Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
- Entrada Therapeutics Reports First Quarter 2024 Financial Results
- Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- Entrada Therapeutics to Present at Upcoming Investor Conferences
- Entrada Therapeutics Promotes Nathan J. Dowden to President
- Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
- Entrada Therapeutics Reports Third Quarter 2023 Financial Results
- Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
- Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community
More ▼
Key statistics
On Thursday, Entrada Therapeutics Inc (TRDA:NMQ) closed at 15.80, -14.32% below its 52-week high of 18.44, set on Jul 18, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.41 |
---|---|
High | 16.44 |
Low | 15.79 |
Bid | 15.52 |
Offer | 15.90 |
Previous close | 16.38 |
Average volume | 84.51k |
---|---|
Shares outstanding | 33.76m |
Free float | 28.16m |
P/E (TTM) | 24.66 |
Market cap | 522.25m USD |
EPS (TTM) | 0.6273 USD |
Data delayed at least 15 minutes, as of Jun 06 2024 21:00 BST.
More ▼